Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
ErbB Enzyme Assay from US Patent US11834453: "Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors"
Assay data:483 Active, 479 Activity ≤ 1 µM, 483 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by DepositorRelated BioAssays by Target
Biochemical Assay from US Patent US11834453: "Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors"
Assay data:483 Active, 483 Activity ≤ 1 µM, 483 Tested
Enzyme-linked immunosorbent assays (ELISA) from US Patent US20230382923: "FUSED TETRACYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2"
Assay data:55 Active, 53 Activity ≤ 1 µM, 55 Tested
HER2 Kinase Activity Assay from US Patent US20230364079: "COMPOUND AS BRAIN-PERMEABLE BTK OR HER2 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF"
Assay data:6 Active, 6 Activity ≤ 1 µM, 6 Tested
Detection of Phosphorylated ERBB2 (pERBB2) from US Patent US11807649: "Fused tetracyclic quinazoline derivatives as inhibitors of ErbB2"
Assay data:57 Active, 55 Activity ≤ 1 µM, 57 Tested
BT474 Cellular Assay (HER2 Inhibition) from US Patent US11723908: "Quinazoline derivatives as antitumor agents"
Assay data:52 Active, 52 Activity ≤ 1 µM, 52 Tested
Inhibitory Effect on HER2-Phosphorylating Activity (In Vitro) from US Patent US11696917: "Agent enhancing antitumor effect using pyrazolo[3,4-d]pyrimidine compound"
Assay data:79 Active, 79 Activity ≤ 1 µM, 79 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by Target
Enzyme-linked immunosorbent assay (ELISA) from US Patent US11655239: "Fused ring pyrimidine amino compound and preparation method, pharmaceutical composition, and use thereof"
Assay data:32 Active, 18 Activity ≤ 1 nM, 32 Activity ≤ 1 µM, 32 Tested
Inhibition of EGFR and HER2 Kinase Activity Assay from US Patent US11548900: "Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof"
Assay data:137 Active, 137 Activity ≤ 1 µM, 137 Tested
Kinase Assay for ErbB2 from US Patent US11524956: "Alkyne substituted quinazoline compound and methods of use"
Assay data:7 Active, 7 Activity ≤ 1 µM, 7 Tested
In vitro kinase inhibition assay from US Patent US11505527: "Tetrahydroquinoline derivatives and a process of preparation thereof"
Assay data:3 Active, 3 Activity ≤ 1 nM, 3 Activity ≤ 1 µM, 3 Tested
Inhibition of HER2 (unknown origin) incubated for 1 hr in presence of ATP by Kinase-Glo Plus luminescence kinase assay
Assay data:2 Active, 2 Activity ≤ 1 nM, 2 Activity ≤ 1 µM, 2 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Inhibition of Her2 in human MCF7 cells by SDS-PAGE analysis
Assay data:1 Tested
SummaryPubMed CitationRelated BioAssays by Target
Inhibition of HER2 (unknown origin)
Assay data:1 Active, 1 Activity ≤ 1 µM, 1 Tested
Assay data:7 Active, 6 Activity ≤ 1 µM, 7 Tested
Inhibition of HER2 (unknown origin) at 10 ug/ml using synthetic biotinylated peptide as substrate by Wallac Victor II 1420 microplate reader method relative to control
Assay data:2 Tested
Selectivity interaction (33P-ATP and filter-binding assay (Reaction Biology)) EUB0000646a ERBB2
Selectivity interaction (Z?-LYTE assay) EUB0000638a ERBB2
Selectivity interaction (KinomeScan (DiscoverX)) EUB0000638a ERBB2
SummaryRelated BioAssays by Target
Affinity Biochemical interaction (Competition binding assay (DiscoverX)) EUB0000596aBDA ERBB2
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on